NCT04403061 (Resistir) is a clinical trial of Cytokines measurement in Disease, Viral, sponsored by Asociacion para el Estudio de las Enfermedades Infecciosas.

Who is sponsoring NCT04403061?

NCT04403061 is sponsored by Asociacion para el Estudio de las Enfermedades Infecciosas.

What drugs are being tested in NCT04403061?

Interventions in NCT04403061: Cytokines measurement, Cellular response, TLRs activation measurement, KIR phenotype evaluation.

What condition does NCT04403061 study?

NCT04403061 studies Disease, Viral, Cytokine Release Syndrome, TLRs.

Is NCT04403061 still recruiting?

NCT04403061 is currently completed. Last updated 12 January 2021.

Last reviewed 2021-01-12 · How we verify

NCT04403061: Resistir

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome

Completed Last updated 12 January 2021

What this trial tests

trial testing Cytokines measurement in Disease, Viral in 106 participants. Completed in 10 January 2021.

Timeline

22 May 2020

Primary endpoint
22 December 2020

10 January 2021

Quick facts

Lead sponsor	Asociacion para el Estudio de las Enfermedades Infecciosas
Status	Completed
Study type	OBSERVATIONAL
Enrollment	106
Start date	22 May 2020
Primary completion	22 December 2020
Estimated completion	10 January 2021
Sites	1 location across Spain

Drugs / interventions tested

Cytokines measurement
Cellular response
TLRs activation measurement
KIR phenotype evaluation

Conditions studied

Disease, Viral — all drugs for Disease, Viral →
Cytokine Release Syndrome — all drugs for Cytokine Release Syndrome →
TLRs — all drugs for TLRs →

Sponsor

Asociacion para el Estudio de las Enfermedades Infecciosas

Who can join

Adults 18 to 100, any sex, with Disease, Viral or Cytokine Release Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To ascertain globally the changes in the cytokines involved and TLRs/KIR activation in patients admitted to the hospital with a COVID-19 diagnosis, and the changes after initiation of the different therapies

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

T-cell responses and therapies against SARS-CoV-2 infection.
Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, et al · · 2021 · cited 158× · PMID 32935333 · DOI 10.1111/imm.13262

Verify or expand the search:

Other Asociacion para el Estudio de las Enfermedades Infecciosas trials

Trials by the same sponsor.

NCT04526977 — Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis). · unknown
NCT04402827 — Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19. · completed
NCT03348449 — Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04403061 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asociacion para el Estudio de las Enfermedades Infecciosas
Last refreshed: 12 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04403061.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing